B
Best Skin Research, LLC. | Camp Hill, PA
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Deucravacitinib
Rocatinlimab
Ustekinumab
RO7790121
Ruxolitinib
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 4 total trials
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab
The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic...
Enrolling
Atopic Dermatitis
Drug: Afimkibart
Drug: Placebo
A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
Enrolling
Plaque Psoriasis
Drug: Ustekinumab
Drug: Deucravacitinib
Trial sponsors
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems